Calcium, phosphorus, cardiovascular events and all-cause mortality in hemodialysis patients: A single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy guidelines

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 1, 2008, Pages 42-48

  Komaba, Hirotaka ^a,b   Igaki, Naoya ^a   Takashima, Mototsugu ^a   Goto, Shunsuke ^a   Yokota, Kazuki ^a   Komada, Hisako ^a   Takemoto, Toshiyuki ^a   Kohno, Maki ^a   Kadoguchi, Hiraku ^a   Hirosue, Yoshiaki ^a   Goto, Takeo ^a  

^a Takasago Municipal Hospital   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcium; Cardiovascular event; Hemodialysis patient; JSDT guidelines; Phosphorus; Secondary hyperparathyroidism

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORTALITY; PRIORITY JOURNAL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CALCIUM; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 38849123291     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2007.00539.x     Document Type: Article

References (17)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998 13 : 607 17.
2. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001 12 : 2131 8.
3. Massry S. K/DOQI clinical practice guidelines. Am J Kidney Dis 2003 42 : 1 201.
4. Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan. An overview of regular dialysis treatment in Japan as of 31 December 2003. Ther Apher Dial 2005 9 : 431 58.
5. Fukagawa M, Akizawa T. How to apply and adapt international guidelines on bone metabolism and disease to the management of Japanese dialysis patients. Ther Apher Dial 2005 9 : 1 2.
6. Yokoyama K, Katoh N, Kasai K et al. The influences of method of calcium correction and the timing of blood collection on application of the K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Japan. Ther Apher Dial 2006 10 : 257 61.
7. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973 15 : 643 6.
8. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004 15 : 2208 18.
9. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005 16 : 1788 93.
10. Ketteler M, Westenfeld R, Schlieper G, Brandenburg V. Pathogenesis of vascular calcification in dialysis patients. Clin Exp Nephrol 2005 9 : 265 70.
11. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000 87 : E10 17.
12. Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003 63 : 1003 11.
13. Kurz P, Monier-Faugere MC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994 46 : 855 61.
14. Guh JY, Chen HC, Chuang HY, Huang SC, Chien LC, Lai YH. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis 2002 39 : 1245 54.
15. Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006 69 : 1222 8.
16. Izumi M, Shirai K, Ito K et al. Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines. Ther Apher Dial 2005 9 : 24 31.
17. Hamano T, Fujii N, Ito T, Imai E. Different routes bridging calcium in Japanese hemodialysis patients. Ther Apher Dial 2005 9 : 32 8.